| abstract |
The present invention provides antigen binding proteins, e.g., T cell receptors (TCRs), specifically binding SARS-CoV-2 antigenic peptides in the context of HLA molecules. The antigen binding proteins are highly efficacious by conferring potent effector functions on immune cells, e.g., T cells, and can be used in adoptive cell therapy (ACT) for the treatment of COVID-19, e.g. independent of the overall immune status of the COVID-19 patient. In particular, the antigen binding proteins specifically bind SARS-CoV-2 antigenic peptides and induce interferon-γ release. The antigen binding proteins induce strong signaling upon binding of the SARS-CoV-2 antigenic peptide as well as a cytotoxic response upon binding of the antigenic peptide. |